Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Benzinga.com  December 14, 2018

GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates

Business Wire December 4, 2018

GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting

Business Wire December 3, 2018

GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018

Business Wire November 29, 2018

Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors

Business Wire November 28, 2018

GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

Business Wire November 19, 2018

Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP — Future Expectations, Projections Moving into 2018

GlobeNewswire November 6, 2018

GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements

Business Wire November 2, 2018

GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting

Business Wire November 1, 2018

GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018

Business Wire October 26, 2018

GlycoMimetics to Present at Upcoming Investor Conferences

Business Wire October 24, 2018

Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire August 31, 2018

GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

Business Wire August 14, 2018

GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements

Business Wire August 9, 2018

GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018

Business Wire August 2, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Minerals Technologies, USG, Continental Resources, Take-Two Interactive Software, Trimble, and GlycoMimetics — New Research Emphasizes Economic Growth

GlobeNewswire July 27, 2018

GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference

Business Wire June 1, 2018

GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy

Business Wire May 30, 2018

GlycoMimetics Reports First Quarter 2018 Results

Business Wire May 3, 2018

GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018

Business Wire April 26, 2018